Sei Investments Co. Makes New $1.09 Million Investment in BioAge Labs, Inc. $BIOA

Sei Investments Co. purchased a new stake in BioAge Labs, Inc. (NASDAQ:BIOA) in the 1st quarter, Holdings Channel reports. The firm purchased 62,385 shares of the company’s stock, valued at approximately $1,091,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BIOA. Vanguard Group Inc. lifted its holdings in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after acquiring an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in BioAge Labs in the fourth quarter valued at approximately $13,892,000. Geode Capital Management LLC increased its position in BioAge Labs by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after purchasing an additional 28,646 shares during the last quarter. State Street Corp raised its stake in BioAge Labs by 113.4% during the fourth quarter. State Street Corp now owns 422,846 shares of the company’s stock worth $5,594,000 after purchasing an additional 224,735 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in BioAge Labs during the fourth quarter worth approximately $5,406,000.

BioAge Labs Stock Down 1.8%

Shares of NASDAQ:BIOA opened at $10.48 on Thursday. The company has a market capitalization of $481.03 million, a price-to-earnings ratio of -4.40 and a beta of 0.93. The company has a 50 day moving average of $19.70 and a two-hundred day moving average of $18.98. BioAge Labs, Inc. has a 52-week low of $4.38 and a 52-week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, equities analysts anticipate that BioAge Labs, Inc. will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on BIOA. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a report on Friday, July 31st. Needham & Company LLC lowered their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, BTIG Research restated a “buy” rating and set a $40.00 price target on shares of BioAge Labs in a research note on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioAge Labs has a consensus rating of “Moderate Buy” and an average target price of $36.57.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.